@phdthesis{Duechs2011,
  author    = {D{\"u}chs, Matthias},
  title     = {Effects of Toll-like receptor agonists on the pathogenesis of atopic asthma in mice},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-66369},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2011},
  abstract  = {In the last decades, both the incidence and the severity of asthma have steadily increased. Furthermore, available therapies only treat the symptoms but do not cure the disease. Immune modulation induced by TLR agonists may be a promising novel approach to effectively treat asthma as it targets the underlying immunopathology directly rather than one mediator alone. The aim of this thesis was to investigate if the immunostimulatory properties of Toll-like receptor (TLR) agonists can be utilized to develop novel therapeutic intervention strategies for the treatment of asthma using murine models of allergic inflammation. For this purpose five different TLR agonists were tested in preclinical mouse models of acute and chronic asthma, both in preventive and therapeutic settings. Firstly, TLR-2, 3, 4, 7/8 and 9 agonists were delivered intratracheally at different doses before pulmonary allergen exposure in the asthma model of acute inflammation. TLR9 agonist CpG-containing oligodeoxynucleotides (CpG) > TLR7 agonist Resiquimod (R848) > TLR3 agonists poly(I:C) strongly reduced allergen induced airway eosinophilia and IL-4 levels in a dose-dependent manner. All TLR agonists increased neutrophil numbers, TLR4 agonist lipopolysaccharide (LPS) > TLR2 agonist lipoteichonic acid (LTA) > poly(I:C) > CpG > R848 and, with the exception of R848, the amount of pro-inflammatory cytokines in the airways. Suppressive effects were not dependent upon IFN-γ and IL-10 or associated with increased numbers of regulatory T cells in the airways. All TLR agonists, except LTA, similarly reduced airway eosinophilia and IL-4 levels when applied therapeutically after allergen challenge. These results show that the TLR agonists have different suppressive effects on TH2 responses in the airways which further depend on the dose and the experimental setup in which they were tested. Interestingly, all agonists induced airway neutrophilia, albeit to different degrees, raising the question if TLR ligands are safe for human use when applied directly into the lung. Different TLR agonists are also being developed for human use as adjuvants combined with allergen in specific immunotherapy. Recent clinical data suggest that this may be achieved by induction of allergen-specific TH1 responses. For this reason, the ability of different TLR agonists to induce allergen-specific TH1 and suppress allergen-specific TH2 responses in a preclinical setting was investigated in this thesis. Different doses of the TLR agonists were applied together with allergen, then mice were exposed to allergen aerosol. CpG > LPS >LTA dose-dependently strongly suppressed the development of airway eosinophilia with poly(I:C) and R848 having no effect. The decrease in eosinophilic numbers was associated withincreased neutrophils present in the airways. IL-4 and IL-5 levels in the bronchoalveolar lavage fluid were also decreased when poly(I:C), LPS, and CpG were used. All TLR agonists increased allergen-specific IgG2a, and with the exception of poly(I:C), reduced allergen-specific IgE levels in the serum. Cutaneous anaphylaxis to allergen was completely prevented when LPS or CpG were given as adjuvant. The strongest TH1 responses were induced by CpG and poly(I:C), characterized by the presence of IFN-γ in the bronchoalveolar lavage and the highest allergen-specific IgG2a levels in the serum. This data supports approaches to use TLR9 or TLR4 agonists for human therapy as adjuvant in combination with allergen in novel specific immunotherapy formulations. In the last part of the thesis, it was investigated if TLR activation can also affect the pathology of severe chronic asthma. Therapeutic administration of R848 or CpG reduced features of inflammation and remodeling. Both agonists showed superior effects to dexamethasone, with CpG being more efficient than R848. This result again supports a TLR9-based therapy as a viable option for the treatment of severe chronic asthma which may present a potential alternative for anti-inflammatory therapy with steroids. Taken together, the results of this thesis support the use of TLR agonists to treat asthma. The most favorable efficacy/safety ratio is to be expected from TLR-based therapies combining TLR4 or TLR9 agonists with allergen in specific immunotherapy. In regard to TLR agonist monotherapy, R848 and CpG showed the most promising profiles, CpG particularly in a model of severe chronic asthma. However, since all TLR agonists used in this study also showed pro-inflammatory potential, the safety aspect of such an approach needs to be taken into account.},
  subject      = {Toll-like Rezeptor},
  language  = {en}
}
@phdthesis{Hahn2003,
  author    = {Hahn, Christian},
  title     = {Die Rolle von IL-4 und IL-13 in Maus-Modellen f{\"u}r allergische Erkrankungen},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-8493},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2003},
  abstract  = {IL-4 und IL-13 sind wichtige Faktoren bei der Entwicklung allergischer Erkrankungen. In dieser Arbeit wird die Rolle von IL-4 und IL-13 in einem Maus-Modell f{\"u}r allergisches Asthma w{\"a}hrend der allergischen Sensibilisierung und in einer etablierten asthmatischen Erkrankung untersucht. Weiterhin wird die Rolle von IL-4 und IL-13 in fr{\"u}hen Stadien der atopischen Dermatitis in einem Maus-Modell betrachtet. In einem Maus-Modell f{\"u}r allergisches Asthma mit anhaltender IgE-Synthese und einer persistierenden allergischen Atemwegspathologie konnte gezeigt werden, dass die Inhibition des IL-4/IL-13 Systems w{\"a}hrend der allergischen Sensibilisierung zu einer dosisabh{\"a}ngigen Reduktion der allergen-spezifischen IgE-Titer, zur Inhibition der Atemwegseosinophilie, zur Reduktion der IL-5-Spiegel in der BAL und zu einer gesenkten Anzahl von IL-4 sezernierenden CD4+ T-Zellen. Weiterhin konnte durch die Inhibition des IL-4/IL-13 Systems die Becherzellmetaplasie signifikant gesenkt werden. Die Inhibition des IL-4/IL-13 Systems nach der Entwicklung der allergischen Atemwegspathologie f{\"u}hrte hingegen nicht zu einer signifikanten Reduktion der gemessenen Allergie-Parameter. Daraus l{\"a}sst sich schließen, dass IL-4 und IL-13 nur eine untergeordnete Rolle in einer etablierten Allergie spielt. Diese Ergebnisse sind insbesondere wichtig, wenn man {\"u}ber das Verwendungspotential eines IL-4/IL-13-Inhibitors in der Allergie-Therapie bei asthmatischen Patienten spekuliert. Weiterhin konnte in dieser Arbeit gezeigt werden, dass die NC/Nga-Maus ein Modell f{\"u}r die humane atopische Dermatitis darstellt. NC/Nga M{\"a}use, die unter konventionellen Bedingungen gehalten wurden, entwickeln makroskopische und histologische Hautpathologien, die der humanen atopischen Dermatitis sehr {\"a}hneln. Weiterhin entwickeln unter konventionellen Bedingungen gehaltenen NC/Nga M{\"a}use hohe IgE-Titer im Serum, die mit einer erh{\"o}hten Produktion an Th2-Zytokinen verbunden war. Die Inhibition des IL-4/IL-13-Systems f{\"u}hrte in diesem Modell jedoch nicht zu einer Reduktion von Symptomen und Pathologien der humanen atopischen Dermatitis. Deswegen kann man spekulieren, dass die Inhibition des IL-4/IL-13-Systems zu einem zu sp{\"a}ten Zeitpunkt erfolgte. Des Weiteren kann eine nicht-standardisierte Sensibilisierung bei M{\"a}usen, die in einer konventionellen Tierhaltung gehalten werden, zu einem sehr unterschiedlichen Ausbruch der Dermatitis f{\"u}hren. Deshalb werden weitere Tierversuche mit einer h{\"o}heren Anzahl von Tieren, die zwischen den W{\"u}rfen randomisiert werden, n{\"o}tig sein, um die Rolle von IL-4 und IL-13 in der atopischen Dermatitis zu kl{\"a}ren.},
  language  = {de}
}
@phdthesis{Noskov2003,
  author    = {Noskov, Andrey},
  title     = {Structural and functional studies of the Interleukin-5 receptor system},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-8195},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2003},
  abstract  = {The aim of current work was contribution to the long-term ongoing project on developing human IL-5 agonists/antagonists that intervene with or inhibit IL-5 numerous functions in cell culture and/or in animal disease models. To facilitate design of an IL-5 antagonist variant or low-molecular weight mimetics only capable of binding to the specific receptor alpha chain, but would lack the ability to attract the receptor common \&\#946;-chain and thus initiate receptor complex activation it is necessary to gain the information on minimal structural and functional epitopes. Such a strategy was successfully adopted in our group on example of Interleukin 4. To precisely localize minimal structural epitope it is essential to have structure of the ligand in its bound form and especially informative would be structure of complex of the ligand and its specific receptor alpha chain. For this purpose large quantities (tens of milligrams), retaining full biological activity IL-5 and extracellular domain of IL-5 specific receptor \&\#945;-chain were expressed in a bacterial expression system (E.coli). After successful refolding proteins were purified to 95-99\% Stable and soluble receptor:ligand complex was prepared. Each established purification and refolding procedures were subjected to optimization targeting maximal yields and purity. Produced receptor:ligand complex was applied to crystallization experiments. Microcrystals were initially obtained with a flexible sparse matrix screening methodology. Crystal quality was subsequently improved by fine-tuning of the crystallization conditions. At this stage crystals of about 800x150x30µm in size can be obtained. They possess desirable visible characteristics of crystals including optical clarity, smooth facecs and sharp edges. Crystals rotate plane polarized light reflecting their well internal organization. Unfortunately relative slimness and sometimes cluster nature of the produced crystals complicates acquisition of high-resolution dataset and resolution of the structure. With some of obtained crystals diffraction to a resolution up to 4{\AA} was observed.},
  subject      = {Interleukin 5},
  language  = {en}
}